Cargando…
Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
OBJECTIVE: To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. METHOD: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716194/ https://www.ncbi.nlm.nih.gov/pubmed/34976097 http://dx.doi.org/10.1155/2021/6203999 |
_version_ | 1784624270258733056 |
---|---|
author | Li, Yi-Fan Hu, Hui-Min Wang, Bo-Ning Zhang, Yi Liu, Xing Mao, Peng Fan, Bi-Fa |
author_facet | Li, Yi-Fan Hu, Hui-Min Wang, Bo-Ning Zhang, Yi Liu, Xing Mao, Peng Fan, Bi-Fa |
author_sort | Li, Yi-Fan |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. METHOD: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. The primary outcome was responder rate, defined as the percentage of migraineurs with 50% or more reduction in the frequency of migraine attack during treatment and posttreatment period compared with the baseline. The secondary outcomes were the number of migraine days, migraine attack frequency, visual analogue scale (VAS), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HAMD), and Migraine Disability Assessment (MIDAS). RESULTS: A total of 346 migraineurs completed the research and were included in the intention-treatment analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group (P < 0.001). No severe adverse events were observed in this trial. CONCLUSION: Chuanxiong Qingnao Granule can significantly improve headache symptoms in patients with migraine while improving disability, fatigue, and depression with a good safety profile. |
format | Online Article Text |
id | pubmed-8716194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-87161942021-12-30 Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial Li, Yi-Fan Hu, Hui-Min Wang, Bo-Ning Zhang, Yi Liu, Xing Mao, Peng Fan, Bi-Fa Evid Based Complement Alternat Med Research Article OBJECTIVE: To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. METHOD: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. The primary outcome was responder rate, defined as the percentage of migraineurs with 50% or more reduction in the frequency of migraine attack during treatment and posttreatment period compared with the baseline. The secondary outcomes were the number of migraine days, migraine attack frequency, visual analogue scale (VAS), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HAMD), and Migraine Disability Assessment (MIDAS). RESULTS: A total of 346 migraineurs completed the research and were included in the intention-treatment analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group (P < 0.001). No severe adverse events were observed in this trial. CONCLUSION: Chuanxiong Qingnao Granule can significantly improve headache symptoms in patients with migraine while improving disability, fatigue, and depression with a good safety profile. Hindawi 2021-12-22 /pmc/articles/PMC8716194/ /pubmed/34976097 http://dx.doi.org/10.1155/2021/6203999 Text en Copyright © 2021 Yi-Fan Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Yi-Fan Hu, Hui-Min Wang, Bo-Ning Zhang, Yi Liu, Xing Mao, Peng Fan, Bi-Fa Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial |
title | Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_full | Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_fullStr | Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_full_unstemmed | Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_short | Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_sort | efficacy and safety of chuanxiong qingnao granule in patients with migraine: a randomized, double-blind, placebo-controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716194/ https://www.ncbi.nlm.nih.gov/pubmed/34976097 http://dx.doi.org/10.1155/2021/6203999 |
work_keys_str_mv | AT liyifan efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial AT huhuimin efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial AT wangboning efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial AT zhangyi efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial AT liuxing efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial AT maopeng efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial AT fanbifa efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial |